Myocardial Infarction

185

Pipeline Programs↗

39

Active Trials↗

63

Companies Involved↗

Myocardial Infarction is a highly competitive landscape with 185 programs across 63 companies. The most active players are Cytori Therapeutics, Taiwan Bio Therapeutics Inc., Lisata Therapeutics, Inc.. 70 therapies are approved with 34 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

80/100

Pipeline Velocity

36/100

Mech. Concentration

6/100

Completion Rate

83/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Cytori Therapeutics

1 program

Taiwan Bio Therapeutics Inc.

1 program

Lisata Therapeutics, Inc.

1 program

Zealand Pharma

1 program

CeleCor Therapeutics

1 program

Athera Biotechnologies AB

1 program

Pipeline

Programs by Phase

Preclinical35

Tenecteplase

Roche

Alteplase

Roche

Enoxaparin Sodium

Sanofi

Caffeine

Hikma Pharmaceuticals LLC

Fluvastatin

Novartis

Phase 14

DPA-714-PET/MRI

University of Alabama at Birmingham

Injection of Adrc's

Cytori Therapeutics

Human BNP

Mayo Clinic

Omnimsc-AMI

Taiwan Bio Therapeutics Inc.

Phase 242

Rivaroxaban

Wim Janssens

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Epoetin Beta

Roche

Nesiritide

Scios, Inc.

Phase 334

Semaglutide

Novo Nordisk

Abciximab

Boehringer Ingelheim

Nicorandil

Merck & Co.

Methylprednisolone

Pfizer

Ezetimibe

Organon and Co

Approved70

Nitroglycerin

Viatris Specialty LLC

Carvedilol

Akero Therapeutics

Niacin

AbbVie

Paroxetine

Sebela Pharmaceuticals Development LLC

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Analysis

Modality Breakdown

88%

Small molecule

184 of 208 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 208 classified programs, each share of the total. Modality classified for 98% of 233 pipeline programs.

Analysis

Trial Status

216

clinical trials

Completed111 · 51%

Unknown status43 · 20%

Recruiting23 · 11%

Withdrawn12 · 6%

Terminated11 · 5%

Active, not recruiting10 · 5%

Other6 · 3%

Clinical Trials

Trial Activity

216 trials

Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05410925·2,260 enrolled

Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion

Recruiting·WWroclaw Medical University·Phase 4·NCT05759078·1,000 enrolled

Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study

Recruiting·FFederico II University·Phase 2/3·NCT07380919·100 enrolled

Rituximab in Patients With ST-elevation Myocardial Infarction

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05211401·372 enrolled

Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

Recruiting·IInstituto Mexicano del Seguro Social·Phase 3·NCT07295223·44 enrolled

Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO

Recruiting·IIRCCS San Raffaele·Phase 2·NCT06792643·50 enrolled

Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

Recruiting·National Institute of Cardiovascular Diseases, Pakistan·Phase 3·NCT06742567·472 enrolled

Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage

Recruiting·RRadboud University Medical Center·N/A·NCT05986968·200 enrolled

Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells As an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients

Recruiting·EEver Supreme Bio Technology Co., Ltd.·Phase 2·NCT06147986·41 enrolled

Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction

Recruiting·—·N/A·NCT06364124·84 enrolled

Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction

Recruiting·HHarbin Medical University·N/A·NCT04912518·250 enrolled

Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction

Recruiting·UUniversity of Aarhus·Phase 4·NCT06710184·5,076 enrolled

Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction

Recruiting·SSeoul National Hospital·Phase 3·NCT06364150·30 enrolled

Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

Recruiting·—·N/A·NCT05665608·3,595 enrolled

Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

Recruiting·MMontreal Heart Institute·Phase 3·NCT07257198·2,570 enrolled

Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)